Diminished Immune Cell Adhesion in Hypoimmune ICAM-1 Knockout Pluripotent Stem Cells

Sayandeep Saha,W. John Haynes,Natalia Del Rio,Elizabeth E Young,Jue Zhang,Jiwon Seo,Liupei Huang,Alexis M Holm,Wesley Blashka,Lydia Murphy,Merrick Scholz,Abigale Henrichs,Jayalaxmi Suresh Babu,John Steill,Ron E Stewart,Timothy J Kamp,Matthew E Brown
DOI: https://doi.org/10.1101/2024.06.07.597791
2024-06-09
Abstract:Hypoimmune gene edited human pluripotent stem cells (hPSCs) are a promising platform for developing reparative cellular therapies that evade immune rejection. Existing first-generation hypoimmune strategies have used CRISPR/Cas9 editing to modulate genes associated with adaptive (e.g., T cell) immune responses, but have largely not addressed the innate immune cells (e.g., monocytes, neutrophils) that mediate inflammation and rejection processes occurring early after graft transplantation. We identified the adhesion molecule ICAM-1 as a novel hypoimmune target that plays multiple critical roles in both adaptive and innate immune responses post-transplantation. In a series of studies, we found that ICAM-1 blocking or knock-out (KO) in hPSC-derived cardiovascular therapies imparted significantly diminished binding of multiple immune cell types. ICAM-1 KO resulted in diminished T cell proliferation responses in vitro and in longer in vivo retention/protection of KO grafts following immune cell encounter in NeoThy humanized mice. The ICAM-1 KO edit was also introduced into existing first-generation hypoimmune hPSCs and prevented immune cell binding, thereby enhancing the overall hypoimmune capacity of the cells. This novel hypoimmune editing strategy has the potential to improve the long-term efficacy and safety profiles of regenerative therapies for cardiovascular pathologies and a number of other diseases.
Immunology
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of human pluripotent stem cell (hPSC) therapies that can evade immune rejection. Existing first-generation immune evasion strategies primarily focus on regulating genes associated with adaptive immune responses (such as T cell-mediated immune responses), but have not adequately addressed the inflammation and rejection processes mediated by innate immune cells (such as monocytes and neutrophils) that play a critical role in the early stages of transplantation. The authors use CRISPR/Cas9 gene editing technology to knock out ICAM-1 (intercellular adhesion molecule-1) to reduce the adhesion of various immune cell types to hPSC-derived cells, thereby enhancing the immune evasion capability of these cells. Specifically, this study aims to: 1. **Validate the role of ICAM-1 in immune cell adhesion**: By using ICAM-1 blocking antibodies, validate the effect of ICAM-1 on immune cell adhesion in hPSC-derived cardiovascular cell therapies (hPSC-CVTs). 2. **Generate ICAM-1 knockout hPSCs**: Utilize CRISPR/Cas9 technology to knock out the ICAM-1 gene, generating hPSCs that lack both surface and secreted ICAM-1 proteins, and verify their immune evasion effect. 3. **Evaluate the differentiation ability and immune response of ICAM-1 knockout hPSCs**: Assess the differentiation ability of ICAM-1 knockout hPSCs and their immune response in vitro and in vivo, particularly their effect on T cell proliferation and graft survival. 4. **Combine with other immune evasion strategies**: Combine ICAM-1 knockout with existing first-generation immune evasion strategies (such as MHC class I and II gene knockout and CD47 overexpression) to evaluate their combined immune evasion effect. Through these studies, the authors hope to develop a novel immune evasion editing strategy to improve the long-term efficacy and safety of regenerative therapies in cardiovascular diseases and other conditions.